Flare Therapeutics Announces Strategic Discovery Collaboration with Roche to Address Previously Undrugged Transcription Factor Targets in Oncology
Flare Therapeutics and Roche have announced a strategic discovery collaboration focusing on transcription factor targets in oncology. The partnership leverages Flare's proteomic and mass spectrometry platform to discover novel small molecule drugs. Flare will receive US$70 million upfront, with potential milestone payments exceeding US$1.8 billion plus royalties. Flare will lead discovery and preclinical activities, while Roche will handle further development and commercialization. Flare retains rights to co-fund development for one target in exchange for increased US royalties, and maintains ownership of its existing pipeline, including FX-909 for urothelial cancer.
Flare Therapeutics e Roche hanno annunciato una collaborazione strategica per la scoperta di nuovi farmaci focalizzandosi su target dei fattori di trascrizione in oncologia. La partnership sfrutta la piattaforma di proteomica e spettrometria di massa di Flare per scoprire nuovi farmaci a piccole molecole. Flare riceverà 70 milioni di dollari upfront, con pagamenti per tappe potenziali che superano 1,8 miliardi di dollari più royalties. Flare guiderà le attività di scoperta e precliniche, mentre Roche si occuperà dello sviluppo e della commercializzazione successivi. Flare mantiene i diritti per co-finanziare lo sviluppo di un target in cambio di royalties maggiorate negli Stati Uniti e conserva la proprietà della propria pipeline esistente, incluso FX-909 per il cancro uroteliale.
Flare Therapeutics y Roche han anunciado una colaboración estratégica de descubrimiento centrada en dianas de factores de transcripción en oncología. La asociación aprovecha la plataforma de proteómica y espectrometría de masas de Flare para descubrir nuevos fármacos de pequeñas moléculas. Flare recibirá 70 millones de dólares por adelantado, con pagos por hitos superiores a 1.8 mil millones de dólares más regalías. Flare liderará las actividades de descubrimiento y preclínicas, mientras que Roche se encargará del desarrollo y la comercialización posterior. Flare retiene los derechos para cofinanciar el desarrollo de una diana a cambio de un aumento en las regalías en EE. UU., y mantiene la propiedad de su pipeline existente, incluido FX-909 para el cáncer urotelial.
Flare Therapeutics와 Roche는 종양학에서 전사 인자 타겟에 중점을 둔 전략적 발견 협력을 발표했습니다. 이 파트너십은 Flare의 단백질체 및 질량 분석 플랫폼을 활용하여 새로운 소분자 약물을 발견합니다. Flare는 7천만 달러의 선급금을 받게 됩니다, 잠재적인 이정표 지급액은 18억 달러를 초과하며 로열티가 추가됩니다. Flare는 발견 및 전임상 활동을 맡고, Roche는 이후 개발 및 상업화를 담당합니다. Flare는 한 개 타겟의 개발을 공동 자금 지원할 권리를 유지하며, 이는 미국에서 증가된 로열티와 맞바꿉니다. 또한, Flare는 FX-909를 포함한 기존 파이프라인의 소유권을 유지합니다.
Flare Therapeutics et Roche ont annoncé une collaboration stratégique de découverte ciblant les facteurs de transcription en oncologie. Ce partenariat tire parti de la plateforme de protéomique et de spectrométrie de masse de Flare pour découvrir de nouveaux médicaments à petites molécules. Flare recevra 70 millions de dollars à l'avance, avec des paiements d'étape potentiels dépassant 1,8 milliard de dollars plus des redevances. Flare dirigera les activités de découverte et précliniques, tandis que Roche s'occupera du développement et de la commercialisation ultérieurs. Flare conserve les droits de cofinancer le développement d'une cible en échange d'une augmentation des redevances aux États-Unis, et maintient la propriété de son pipeline existant, y compris FX-909 pour le cancer urothélial.
Flare Therapeutics und Roche haben eine strategische Entdeckungspartnerschaft angekündigt, die sich auf Transkriptionsfaktorziele in der Onkologie konzentriert. Die Partnerschaft nutzt die Proteomik- und Massenspektrometrie-Plattform von Flare, um neuartige niedermolekulare Medikamente zu entdecken. Flare erhält 70 Millionen USD im Voraus, mit potenziellen Meilensteinzahlungen von über 1,8 Milliarden USD zuzüglich Lizenzgebühren. Flare wird die Entdeckungs- und präklinischen Aktivitäten leiten, während Roche die weitere Entwicklung und Vermarktung übernimmt. Flare behält das Recht, die Entwicklung für ein Ziel co-finanzieren zu lassen, im Austausch für erhöhte US-Royaltys, und behält das Eigentum an seiner bestehenden Pipeline, einschließlich FX-909 gegen Urothelkarzinom.
- Substantial upfront payment of US$70 million
- Potential milestone payments exceeding US$1.8 billion plus royalties
- Strategic partnership with major pharmaceutical company Roche
- Retention of rights to existing pipeline and co-funding option
- Access to Roche's global development and commercialization capabilities
- Development risks transferred to Roche except for co-funded target
- control over development and commercialization decisions
Collaboration will leverage Flare Therapeutics' proteomic and mass spectrometry platform and expertise, powered by its proprietary library of electrophilic compounds, to discover novel small molecules aimed at transcription factor targets in oncology
Flare Therapeutics to receive
"Roche is an ideal partner for Flare Therapeutics because we share a commitment to tackling the most challenging disease areas with novel approaches and overcoming the difficulties of drugging transcription factors. Our platform and expertise have rapidly generated a clinical-stage pipeline, demonstrating the strong potential of our approach. This collaboration will accelerate the expansion of our capabilities, enabling us to develop treatments for transcription factors implicated in indications with high unmet needs. Together with Roche's expertise, our objective is to successfully pursue challenging transcription factor targets, with the ultimate goal of providing novel interventions for patients who are not currently served by standard-of-care therapies," said Rob Sims, Ph.D., Chief Scientific Officer and Co-founder of Flare Therapeutics.
"We are excited to join forces with Flare Therapeutics, combining our leading expertise and global reach in oncology with Flare Therapeutics' deep knowledge in drug discovery for difficult-to-drug transcription factor targets. Transcription factors play a crucial role in various oncological diseases and have the potential to address high unmet medical needs. We are looking forward to developing therapeutic options never possible before," said Boris L. Zaïtra, Head of Roche Corporate Business Development.
As part of the collaboration, Flare Therapeutics will receive a
Additionally, Flare Therapeutics retains a right to co-fund development for one target under the collaboration in exchange for increased royalties in
About Flare Therapeutics Inc.
Flare Therapeutics is a biotechnology company exclusively focused on drugging transcription factors to fully unlock the therapeutic potential of this previously elusive target class. Flare Therapeutics' integrated discovery engine converges rich genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare Therapeutics' proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to Flare Therapeutics. Since its inception, Flare Therapeutics has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that is currently in a Phase I study. Additionally, Flare Therapeutics has advanced a second program with a differentiated mechanism for prostate cancer entering the Investigational New Drug (IND)-enabling stage, along with an earlier-stage portfolio targeting transcription factors involved in oncology and other therapeutic areas. For more information, please visit www.flaretx.com and follow us on LinkedIn.
Investors:
investorrelations@flaretx.com
Media:
Peg Rusconi
peg.rusconi@deerfieldgroup.com
Deerfield Group
View original content to download multimedia:https://www.prnewswire.com/news-releases/flare-therapeutics-announces-strategic-discovery-collaboration-with-roche-to-address-previously-undrugged-transcription-factor-targets-in-oncology-302301901.html
SOURCE Flare Therapeutics
FAQ
What is the value of the Flare Therapeutics and Roche (RHHBY) collaboration deal?
What is the focus of the Flare Therapeutics and Roche (RHHBY) collaboration?
What rights does Flare Therapeutics retain in the Roche (RHHBY) collaboration?
